Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $11K (cash outflow) fell 97.1% year over year, behind the -70.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 83.6% from the prior quarter. Over 3 fiscal years it compounded at -68.9% a year.
Context
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -97.1% toward the trailing-twelve-month pace of -70.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (618K) USD
- Year-over-year change
- +39.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (618K) | +39.7% |
| FY2024 | 2024-12-31 | (1.03M) | +17.3% |
| FY2023 | 2023-12-31 | (1.24M) | +94.0% |
| FY2022 | 2022-12-31 | (20.63M) | +17.9% |
| FY2021 | 2021-12-31 | (25.12M) | — |
Capital Expenditures vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 capital expenditures of $246K is the 7th largest of the 11 companies compared; the peer median is $610K.
- Its year-over-year change of -70.9% is the 6th highest of 10, against a peer median of -41.0%.
- Capital expenditures amounts to 109.3% of revenue for TNYA, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.51M | +140.5% | +294.4% | 51.6% | |
| LTM Mar 2026 | $1.95M | -4.2% | +1.4% | 5.3% | |
| LTM Mar 2026 | $1.77M | -93.4% | +82.4% | 2.6% | |
| LTM Mar 2026 | $1.57M | -7.4% | -18.1% | — | |
| LTM Mar 2026 | $831K | -41.0% | -5.5% | 41.2% | |
| LTM Mar 2026 | $389K | -91.5% | -40.5% | 3.5% | |
| LTM Mar 2026 | $246K | -70.9% | -68.9% | 109.3% | |
| LTM Mar 2026 | $213.21K | +278.4% | -42.4% | — | |
| LTM Mar 2026 | $22K | -97.4% | -65.4% | 0.1% | |
| LTM Mar 2026 | $20K | -96.2% | -71.9% | 0.1% | |
| LTM Mar 2026 | $9K | — | -88.8% | 0.1% | |
| Peer median (excluding TNYA) | $610K | -41.0% | -29.3% | 3.0% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Depreciation & Amortization | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M |
| Change in Working Capital | 4.74M | (849K) | (5.65M) | (7.93M) | (2.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.6M | 1.66M | (3.28M) | (581K) | (1.43M) |
| Other Working Capital | (3.86M) | (2.51M) | (2.37M) | (7.35M) | (1.03M) |
| Other Non-Cash Items | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M |
| Operating Cash Flow | (60.81M) | (104.42M) | (102.07M) | (90.5M) | (68.26M) |
| Capital Expenditures | (25.12M) | (20.63M) | (1.24M) | (1.03M) | (618K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (213.44M) | (140.48M) | (56.64M) | (87.07M) | 0 |
| Sales of Investments | 0 | 244.75M | 106.62M | 89.21M | 56.7M |
| Other Investing Activities | 0 | 8K | (25K) | 17K | 0 |
| Investing Cash Flow | (238.56M) | 83.65M | 48.72M | 1.13M | 56.08M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.54M | 77.39M | 3.87M | 46.76M | 108.41M |
| Common Stock Repurchased | (13K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 461K | 380K | 181K | 987K | 0 |
| Financing Cash Flow | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.41M) | 57M | (49.31M) | (41.62M) | 96.22M |
| Free Cash Flow | (85.93M) | (125.05M) | (103.31M) | (91.53M) | (68.88M) |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.